1. British Thoracic Society/Scottish Intercollegiate Guidelines Network. SIGN158 British guideline on the management of asthma (2019 update).
   Available at https://www.sign.ac.uk/assets/sign158.pdf. Accessed July 2020.
2. Hoskins G, Williams B, Jackson C, et al. Assessing asthma control in UK primary care: use of routinely collected prospective observational consultation data to determine appropriateness of a variety of control assessment models. BMC Family Practice 2011;12:105–16.
3. Global Initiative for Asthma. Global strategy for asthma management and prevention (2020 update). Available at https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf. Accessed July 2020. Online appendix (2020) available at https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-Appendix_final-wms.pdf. Accessed July 2020.
4. Asthma UK. Indoor asthma triggers. Available at www.asthma.org.uk/advice/triggers/indoor-environment/. Accessed July 2019.
5. Easyhaler Budesonide 100 mcg. Summary of Product Characteristics. Orion Pharma (UK) Limited. August 2018.
6. Montelukast 5 mg chewable tablets. Summary of Product Characteristics. Aurobindo Pharma – Milpharm Ltd. August 2017.
7. SPIRIVA^® Respimat^® 2.5 microgram, inhalation solution. Summary of Product Characteristics. Boehringer Ingelheim Limited. September 2019.
8. Szefler SJ, Vogelburg C, Bernstein JA et al. Tiotropium is efficacious in 6- to 17-year olds with asthma, independent of T2 phenotype. J Allergy Clin Immunol Pract 2019;7(7):2286–95.
9. Davidson WJ, The S, Leigh R. Establishing a normal range for induced sputum cell counts in Western Canada. Can Respir J 2013;20(6):424–8.
10. Tliba O, Panettieri RA. Paucigranulocytic asthma: uncoupling of airway obstruction from inflammation. J Allergy Clin Immunol 2019;143(4):1287–94.
11. Uniphyllin Continus 200 mg prolonged release tablets. Summary of Product Characteristics. Napp Pharmaceuticals Limited. April 2017.
12. Kerstjens HAM, Moroni-Zentgraf P, Tashkin DP et al. Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics I including age, degree of airway obstruction, and allergic status. Respir Med 2016;117:198–206.
13. Xolair 150 mg solution for injection Summary of Product Characteristics. Novartis Pharmaceuticals UK Ltd. August 2019.

BMI = body mass index

BTS/SIGN = British Thoracic Society/Scottish Intercollegiate Guidelines Network

COPD = chronic obstructive pulmonary disease

DPI = dry powder inhaler

FEV₁ = forced expiratory volume in 1 second

FVC = forced vital capacity

GINA = Global INitiative for Asthma

ICS = inhaled corticosteroids

IgE – immunoglobulin E

LABA = long-acting beta-2 agonist

LTRA = leukotriene receptor antagonist

RAST = radioallergosorbent test

SABA = short-acting beta-2 agonist